Previous Close | 5.31 |
Open | 5.22 |
Bid | 5.33 x 100 |
Ask | 5.51 x 100 |
Day's Range | 5.20 - 5.50 |
52 Week Range | 4.05 - 9.94 |
Volume | |
Avg. Volume | 53,195 |
Market Cap | 103.405M |
Beta (5Y Monthly) | -0.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | May 24, 2022 |
1y Target Est | N/A |
ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call Transcript March 15, 2024 ProPhase Labs, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $-0.27. PRPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Noella Alexander-Young: Hello, and good […]